Evidence map›Paper›PMID 34871089›Full record

Trial reportAntimicrobial agents and chemotherapy2022

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

Johan Lombaard, Francis Ssali, Puthanakit Thanyawee, Jan Fourie, Simon Vanveggel, Cornelia Linthicum, Veerle Van Eygen, Rodica Van Solingen-Ristea

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Johan LombaardJosha Research, Bloemfontein, South Africa.ORCID 0000-0002-3229-7182
Francis SsaliJoint Clinical Research Centre, Kampala, Uganda.
Puthanakit ThanyaweeThai Red Cross AIDS Research Centre, Bangkok, Thailand.
Jan FourieJan Fourie Medical Practice, Dundee, South Africa.
Simon VanveggelJanssen Research & Development, Beerse, Belgium.
Cornelia LinthicumJanssen Vaccines AG, Bern, Switzerland.
Veerle Van EygenJanssen Research & Development, Beerse, Belgium.
Rodica Van Solingen-RisteaJanssen Research & Development, Beerse, Belgium.
Janssen (Belgium) · BEJanssen (Switzerland) · CHJoint Clinical Research Centre · UGThai Red Cross Society · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (≥12 to <18 years of age) were treated with RPV at 25 mg once daily (q.d.) plus 2 NRTIs and entered the treatment extension period for up to 240 weeks, with visits every 3 months. Long-term safety (analysis of adverse events [AEs] and laboratory results), efficacy (virologic response and outcome for patients with viral loads of <50 and <400 by time to loss of virologic response [TLOVR] and FDA Snapshot methods, as well as CD4

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAdolescentAnti-Retroviral AgentsHumansRilpivirineTreatment OutcomeViral LoadAnti-HIV AgentsAnti-Retroviral AgentsRilpivirineadolescentsantiretroviral therapyefficacyHIV-1rilpivirinesafety

Identifiers

PMID34871089
PMCPMC8846324
OpenAlexW4200316133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.